Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing
- PMID: 26407589
- DOI: 10.1158/2326-6066.CIR-15-0099-T
Simultaneous Targeting of FcγRs and FcαRI Enhances Tumor Cell Killing
Abstract
Efficacy of anticancer monoclonal antibodies (mAb) is limited by the exhaustion of effector mechanisms. IgG mAbs mediate cellular effector functions through FcγRs expressed on effector cells. IgA mAbs can also induce efficient tumor killing both in vitro and in vivo. IgA mAbs recruit FcαRI-expressing effector cells and therefore initiate different effector mechanisms in vivo compared with IgG. Here, we studied killing of tumor cells coexpressing EGFR and HER2 by the IgG mAbs cetuximab and trastuzumab and their IgA variants. In the presence of a heterogeneous population of effector cells (leukocytes), the combination of IgG and IgA mAbs to two different tumor targets (EGFR and HER2) led to enhanced cytotoxicity compared with each isotype alone. Combination of two IgGs or two IgAs or IgG and IgA against the same target did not enhance cytotoxicity. Increased cytotoxicity relied on the presence of both the peripheral blood mononuclear cell and the polymorphonuclear (PMN) fraction. Purified natural killer cells were only cytotoxic with IgG, whereas cytotoxicity induced by PMNs was strong with IgA and poor with IgG. Monocytes, which coexpress FcγRs and FcαRI, also displayed increased cytotoxicity by the combination of IgG and IgA in an overnight killing assay. Coinjection of cetuximab and IgA2-HER2 resulted in increased antitumor effects compared with either mAb alone in a xenograft model with A431-luc2-HER2 cells. Thus, the combination of IgG and IgA isotypes optimally mobilizes cellular effectors for cytotoxicity, representing a promising novel strategy to improve mAb therapy.
©2015 American Association for Cancer Research.
Similar articles
-
Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.MAbs. 2015;7(4):743-51. doi: 10.1080/19420862.2015.1047570. MAbs. 2015. PMID: 25970007 Free PMC article.
-
IgA EGFR antibodies mediate tumour killing in vivo.EMBO Mol Med. 2013 Aug;5(8):1213-26. doi: 10.1002/emmm.201201929. EMBO Mol Med. 2013. PMID: 23918228 Free PMC article.
-
FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.Blood. 1997 Dec 1;90(11):4485-92. Blood. 1997. PMID: 9373259
-
G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).J Hematother. 1995 Oct;4(5):415-21. doi: 10.1089/scd.1.1995.4.415. J Hematother. 1995. PMID: 8581378 Review.
-
[Characterization of Therapeutic Monoclonal Antibodies by Using FcγR-expressing Reporter Cell Lines].Yakugaku Zasshi. 2017;137(7):837-843. doi: 10.1248/yakushi.16-00252-4. Yakugaku Zasshi. 2017. PMID: 28674297 Review. Japanese.
Cited by
-
Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo.MAbs. 2018 Apr;10(3):453-462. doi: 10.1080/19420862.2018.1433974. Epub 2018 Mar 19. MAbs. 2018. PMID: 29553863 Free PMC article.
-
TERT Mutation Is Accompanied by Neutrophil Infiltration and Contributes to Poor Survival in Isocitrate Dehydrogenase Wild-Type Glioma.Front Cell Dev Biol. 2021 Apr 30;9:654407. doi: 10.3389/fcell.2021.654407. eCollection 2021. Front Cell Dev Biol. 2021. PMID: 33996815 Free PMC article.
-
The Functional Role of IgA in the IgM/IgA-Enriched Immunoglobulin Preparation Trimodulin.Biomedicines. 2021 Dec 3;9(12):1828. doi: 10.3390/biomedicines9121828. Biomedicines. 2021. PMID: 34944644 Free PMC article.
-
IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models.J Immunother Cancer. 2023 Jul;11(7):e006948. doi: 10.1136/jitc-2023-006948. J Immunother Cancer. 2023. PMID: 37479484 Free PMC article.
-
Potent Fc Receptor Signaling by IgA Leads to Superior Killing of Cancer Cells by Neutrophils Compared to IgG.Front Immunol. 2019 Apr 11;10:704. doi: 10.3389/fimmu.2019.00704. eCollection 2019. Front Immunol. 2019. PMID: 31031746 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous